Fund Growth Capital VCT

Verici Dx plc

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon…

Ten80 Group

The company is a SAP focussed on-demand outcome-based delivery solution. Its aim is to connect every SAP customer with every SAP consultant globally, delivering outcome-based projects rather than time-driven costs through the contractor or freelancer marketplace. The SAP global consultancy…

SolasCure

SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. Chronic wounds impact over 40 million people worldwide, with care consuming around 10% of health care expenditure in…

Scancell Holdings plc

Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications and development of a vaccine for COVID-19. ImmunoBody® vaccines target dendritic cells and stimulate…

Qudini

Founded in 2012, Qudini is a B2B software company that provides customer experience SaaS solutions to organisations in retail, hospitality, the public sector and healthcare. Qudini provides a software solution for appointment bookings, queue management, event management and task management…

ProBiotix Health plc

ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. ProBiotix Health’s…

Oxford Biodynamics plc

Oxford BioDynamics is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology checkpoint…

OR Productivity plc

Freehand 2010 acquired the business of Freehand Surgical Ltd following the latter being placed in administration in December 2010. Freehand is positioning itself to become the leading supplier of low cost robotic laparoscope controllers for use by keyhole surgeons. Freehand…

Omega Diagnostics Group plc

Omega Diagnostics Group plc, through its subsidiaries, engages in the manufacture, development, and distribution of medical diagnostic products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Disease. The Allergy and Autoimmune segment engages in the…

Northcoders plc

Northcoders is a market leading provider of coding and software development training for businesses and individuals. Founded in 2015, its business model operates a hybrid structure with a flagship site in Manchester and other sites in Leeds, Birmingham and Newcastle supported…

Microarray Ltd

Archimed was a spin-out from Insense (qv) to commercialise wound dressing technology developed by Insense for the chronic wound care market – this is a growing market due to, inter alia, the increasing average age of populations and the growing…

Insense Ltd

Insense Ltd is an innovative, biotechnology company with a proven track record in taking ideas from drawing board to market. Founded in 2001 by Professor Paul Davis, Insense is based at Colworth Science Park in Bedfordshire, UK. The company owns…

Immunobiology Ltd

ImmunoBiology is a biotechnology company that is focused on developing products that could have applications in the treatment of a range of infectious diseases such as meningitis, tuberculosis, influenza and hepatitis C. The company’s technology is based on a the…

HubBox

HubBox has developed plug-and-play software that gives shoppers a choice between home delivery and local pickup when they check-out on a retailer’s website. This software has been created in conjunction with the largest global delivery network providers (including UPS and…

Geomiq Limited

Geomiq was founded in London in 2017, with the goal of transforming and streamlining the manufacturing industry. Since then, it has become the digital manufacturing platform of choice for over 1200+ professional engineers and procurement teams from over 500 fast-moving…

Genedrive plc

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen…

Gelion plc

awarded the Australian Prime Minister’s Prize for Innovation 2020. Gelion is a global renewable-energy storage innovator. By designing leading-edge battery technology for stationary and mobile energy, the Company supports the transition to a sustainable economy while delivering value for customers…

Fuel 3D Technologies Ltd

Eykona was founded in 2007 to deploy computer vision technology (essentially 3D imaging) developed within Oxford University for developing a hand held camera to measure the volume of chronic wounds – this is a vital measurement for obtaining an understanding…

Forma-Care (UK) Limited

Forma-Care, established in 2019 and based in Durham, provides adult incontinence products to the UK healthcare sector and has established itself as a supplier both to the NHS (for its home delivery service and acute services) and direct to consumer.…

Exosect

Exosect focuses on the development and sales of intelligent and environmentally-friendly pest management solutions. Its products help growers, food producers and processors reduce their use of insecticides. Based on research carried out in Biological Sciences, the company’s products were developed…

Engage XR Holdings plc

ENGAGE XR Holdings plc is metaverse technology company focused on becoming a leading global provider of virtual communications solutions through its new fully featured corporate metaverse, ENGAGE Link. The Company also has a proprietary software platform, ENGAGE, which provides users…

Directa Plus plc

Directa Plus is one of the largest producers and suppliers worldwide of graphene nanoplatelets-based products for use in consumer and industrial markets. The graphene nanoplatelets-based products are natural, chemical-free and sustainably produced. The production process is designed to meet large…

Clean Power Hydrogen plc

CPH2 is a rapidly-growing UK-based technology and manufacturing company which is focussed on the commercial production of “green” hydrogen in a simple, safe, and sustainable manner using its IP-protected Membrane-Free ElectrolyserTM (“MFE”) technology. A decade of dedicated research and product…

Celadon Pharmaceuticals plc

Celadon Pharmaceuticals plc is a UK based pharmaceutical company targeting the research, cultivation, manufacturing and supply of cannabinoid-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based…

Bidstack Group plc

Bidstack is an advertising technology company which provides dynamic, targeted and automated native in-game advertising for the global video games industry across multiple platforms. Its proprietary technology is capable of inserting advertisements within video games.  Bidstack’s customers are games publishers…

Bright Network

Bright Network is a media technology platform which enables blue-chip employers to reach, identify and recruit high-quality graduates and young professionals. London-based Bright Network is led by serial entrepreneur James Uffindell, who previously established, grew, and successfully exited from another…

Arecor Ltd

Arecor was a spin-out from Insense (qv) to commercialise technology developed by Insense for enabling biologics to maintain their integrity without the need for refrigeration – this both reduces cost and also helps deployment in developing countries where temperature monitored…

Aptamer Group plc

Aptamer is a leader in the provision of aptamer discovery services and the development of aptamer-based reagents. The Group solves intractable problems for biotech and big pharma by developing molecular binders called aptamers, as an alternative to antibodies which fail…

Alderley Lighthouse Labs

Alderley Lighthouse Labs was founded by Mark Wigglesworth and Simon Chapman who were previously given responsibility during Covid-19 for establishing the emergency ‘Lighthouse’ capability at Alderley Park; a ‘super-lab’ created from scratch that grew to accommodate over 750 staff members…

ADC Biotechnology

ADC Biotechnology is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an…

Abingdon Health

Abingdon Health (AIM: ABDX) is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial…

SilkFred

Silkfred is an online marketplace for independent ladies’ fashion brands. The business was founded in 2011 with the aim of creating an efficient marketplace for emerging fashion designers to bring products to market and establish their brand in the sector.…

Poolbeg Pharma plc

Poolbeg Pharma is a clinical-stage pharmaceutical company focused on the development and commercialisation of therapies to treat and prevent infectious diseases. Headquartered in London, the business is a spin out from Open Orphan plc and the management team has proven…

Polarean Imaging plc

Polarean Imaging plc is a healthcare technology company which has developed a state of the art proprietary drug-device combination addressing a specific global unmet need in the field of healthcare. The company’s technology has been developed over a number of…

OptiBiotix Health

OptiBiotix (AIM:OPTI) was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease. The aim of OptiBiotix is to discover and…

Old St Labs

Old St Labs is a provider of cloud based, supplier collaboration tools for large, blue chip customers, enabling them to manage key supplier relationships and strategic project work. The core product, Vizibl, seeks to make supplier collaboration much more straight forward,…

Fabacus

Fabacus is an independent software company that has developed a complete product lifecycle solution: Xelacore, aimed at bringing transparency to supply chain networks, with an initial focus on resolving the interaction and information flow between global licensors and their licensees.…

TheraCryf

TheraCryf is based in Liverpool, at the Liverpool Science Park and was founded in 2007 by Dr Stephen Franklin. TheraCryf is a clinical stage drug development company whose lead programmes are in cancer and subarachnoid haemorrhage (a type of stroke).…

Velocity Composites

Velocity Composites PLC (LON:VEL), makes composites that keep the parts of an aeroplane together. Started in 2007 by three engineers who specialise in composites, the company operates out of its headquarters in Burnley and a facility in Fareham. Its clients…

SkinBioTherapeutics

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain. SkinBioTherapeutics’ platform applies research discoveries made on the activities of…

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance. Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such. Please confirm that you understand this warning and wish to proceed.

I understand



Risk summary

(Estimated reading time: 2 minutes)

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this type of investment to be high risk.

What are the key risks?

  1. You could lose all the money you invest
    •  If the business you invest in fails, you are likely to lose 100% of the money you invested.
    • Advertised rates of return aren’t guaranteed. If a borrower doesn’t pay you back as agreed, you could earn less money than expected or nothing at all. In addition, if the tenant of the property being financed doesn’t pay the rent due as agreed or vacates the premises, you could earn less money than expected. A higher advertised rate of return means a higher risk of losing your money.
  2. You are unlikely to be protected if something goes wrong
    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker at https://www.fscs.org.uk/check/investment-protection-checker/.
    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection at https://www.financial-ombudsman.org.uk/consumers.
  3. You won’t get your money back quickly
    • This type of business could face cash-flow problems that delay payments to investors. It could also fail altogether and be unable to repay any of the money owed to you.
    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.
    • Even if you are able to sell your investment early, you may not receive all of your money back or the full value of your investment. In addition, you may have to pay exit fees or additional charges.
    • The most likely way to get your money back is if the business is wound up following the sale of the underlying property or is bought by another business. Neither is guaranteed to happen with the envisaged timescale or at all.
    • Depending upon how your investment is structured and the rate and frequency of any interest paid, it could take 10 years or longer to receive back an amount equal to the amount you invested. You should not expect to get your money back through the payment of dividends.
  4. This is a complex investment
    • This makes it difficult to predict how risky the investment is, but it will most likely be high.
    • You may wish to get financial advice before deciding to invest.
  5. Don’t put all your eggs in one basket
    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.
    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments. (See www.fca.org.uk/investsmart/5-questions-ask-you-invest).

If you are interested in learning more about how to protect yourself, visit the FCA’s website at www.fca.org.uk/investsmart

Request details of upcoming investments– Seneca Select EIS Portfolio Service

Application Form Request – Seneca Select EIS Portfolio Service


Risk summary

(Estimated reading time: 2 minutes)

Due to the potential for losses, the Financial Conduct Authority (“FCA”) considers this investment to be high risk.

What are the key risks?

  1. You could lose all the money you invest
    • If a business you invest in fails, you are likely to lose 100% of the money you invested in that business. Most start-up businesses fail. 
  2. You are unlikely to be protected if something goes wrong
    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker at https://www.fscs.org.uk/check/investment-protection-checker/.
    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection at https://www.financial-ombudsman.org.uk/consumers.
  3. You won’t get your money back quickly
    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.
    • For companies whose shares are not listed on any exchange (‘unquoted’ or ‘private’ companies), the most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.
    • For companies whose shares are listed on an exchange (such as the AQSE or AIM), the most likely way to get your money back is if the business is bought by another business or your shares are sold on that exchange. The latter can only occur if there is a willing buyer.
    • If you are investing in a start-up or EIS qualifying business, you should not expect to get your money back through dividends. Such businesses rarely pay these.
  4. Don’t put all your eggs in one basket
    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.
    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments. (See https://www.fca.org.uk/investsmart/5-questions-ask-you-invest).
  5. The value of your investment can be reduced
    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.
    • These new shares could have additional rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website at www.fca.org.uk/investsmart

Risk summary

(Estimated reading time: 2 minutes)

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.

What are the key risks?

  1. You could lose all the money you invest
    • If the business you invest in fails, you are likely to lose 100% of the money you invested. Most start-up businesses fail.
    • Advertised rates of return aren’t guaranteed. This is not a savings account. If the business doesn’t pay you back as agreed, you could earn less money than expected or nothing at all. In addition, if the tenant of the property being financed doesn’t pay the rent due as agreed or vacates the premises, you could earn less money than expected. A higher advertised rate of return means a higher risk of losing your money.
  2. You are unlikely to be protected if something goes wrong
    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker at https://www.fscs.org.uk/check/investment-protection-checker/.
    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection at https://www.financial-ombudsman.org.uk/consumers.
  3. You won’t get your money back quickly
    • This type of business could face cash-flow problems that delay payments to investors. It could also fail altogether and be unable to repay any of the money owed to you.
    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.
    • Even if you are able to sell your investment early, you may have to pay exit fees or additional charges.
    • The most likely way to get your money back is if the business is bought by another business or is wound
      up following the sale of the underlying property. These events are not common.
    • If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these. This investment aims to make quarterly repayments that comprise both a partial repayment of capital and interest, although this is not guaranteed. It could take over 14 years to receive back an amount equal to the amount you invested.
  4. This is a complex investment
    • This makes it difficult to predict how risky the investment is, but it will most likely be high.
    • You may wish to get financial advice before deciding to invest.
  5. Don’t put all your eggs in one basket
    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.
    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments. (See https://www.fca.org.uk/investsmart/5-questions-ask-you-invest).

If you are interested in learning more about how to protect yourself, visit the FCA’s website at www.fca.org.uk/investsmart

Important notice

Please note that you have clicked to leave the Seneca Partners website. Seneca Partners Limited is Authorised and Regulated by the Financial Conduct Authority (FCA). The website you have requested to visit is an unregulated Seneca business and you will not therefore be afforded the protections offered by an FCA authorised and regulated business.

Please click ok below to continue to the Seneca Bridging website.

OK

Important notice

Please note that you have clicked to leave the Seneca Partners website. Seneca Partners Limited is Authorised and Regulated by the Financial Conduct Authority (FCA). The website you have requested to visit is an unregulated Seneca business and you will not therefore be afforded the protections offered by an FCA authorised and regulated business.

Please click ok below to continue to the Seneca Trade Partners website.

OK

Risk summary

(Estimated reading time: 2 minutes)

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.

What are the key risks?

  1. You could lose all the money you invest
    • If the business you invest in fails, you are likely to lose 100% of the money you invested.
    • Many of the loans ultimately financed by your investment are made to borrowers who can’t borrow money from traditional lenders such as banks. These borrowers have a higher risk of not paying back their loan.
    • Advertised rates of return aren’t guaranteed. If a borrower doesn’t pay back their loan as agreed, you could earn less money than expected. A higher advertised rate of return means a higher risk of losing your money.
  2. You are unlikely to be protected if something goes wrong
    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker at https://www.fscs.org.uk/check/investment-protection-checker/.
    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection at https://www.financial-ombudsman.org.uk/consumers.
  3. You won’t get your money back quickly
    • Some of the loans financed by your investment will last for several years. You may need to wait for your money to be returned even if the borrower repays on time.
    • Some Managers may give you the opportunity to sell your investment early through a ‘secondary market’, but there is no guarantee you will be able to find someone willing to buy.
    • Even if your agreement is advertised as affording early access to your money, you will only get your money early if someone else wants to buy your shares or the company in which you are invested has sufficient available capital to buy them from you. If no one wants to buy, it could
      take longer to get your money back.
    • If you are investing for growth, you should not expect to get your money back through dividends as the Service is not designed to pay dividends to investors seeking growth. If you are investing for income, it will take at least 25 years to get your money back purely through dividends.
  4. Don’t put all your eggs in one basket
    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.
    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments. (See https://www.fca.org.uk/investsmart/5-questions-ask-you-invest).
  5. The value of your investment can be reduced
    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on the basis on which these new shares are issued.
    • If these new shares have additional rights that your shares don’t have, such as the right to receive a fixed dividend, this could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website at www.fca.org.uk/investsmart

Application Form Request – Seneca IHT Service


Risk summary

(Estimated reading time: 2 minutes)

Due to the potential for losses, the Financial Conduct Authority (“FCA”) considers this investment to be high risk.

What are the key risks?

  1. You could lose all the money you invest
    • If a business you invest in fails, you are likely to lose 100% of the money you invested in that business. Most start-up businesses fail. Please see page 14 of the Information Memorandum for an overview of the types of businesses this fund invests in.
  2. You are unlikely to be protected if something goes wrong
    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker at https://www.fscs.org.uk/check/investment-protection-checker/.
    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection at https://www.financial-ombudsman.org.uk/consumers.
  3. You won’t get your money back quickly
    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.
    • The most likely way to get your money back is if the business is bought by another business or your shares are sold on the Alternative Investment Market. The latter can only occur if there is a willing buyer.
    • If you are investing in a start-up or EIS qualifying business, you should not expect to get your money back through dividends. Such businesses rarely pay these.
  4. Don’t put all your eggs in one basket
    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.
    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments. (See https://www.fca.org.uk/investsmart/5-questions-ask-you-invest).
  5. The value of your investment can be reduced
    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.
    • These new shares could have additional rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website at www.fca.org.uk/investsmart

Application Form Request – Seneca AIM EIS Fund


Application Form Request – Seneca EIS Portfolio Service


Risk summary

(Estimated reading time: 2 minutes)

Due to the potential for losses, the Financial Conduct Authority (“FCA”) considers this investment to be high risk.

What are the key risks?

  1. You could lose all the money you invest
    • If a business you invest in fails, you are likely to lose 100% of the money you invested in that business. Most start-up businesses fail. Please see page 10 of the Information Memorandum for an overview of the types of businesses this fund invests in.
  2. You are unlikely to be protected if something goes wrong
    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker at https://www.fscs.org.uk/check/investment-protection-checker/.
    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection at https://www.financial-ombudsman.org.uk/consumers.
  3. You won’t get your money back quickly
    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.
    • For companies whose shares are not listed on any exchange (‘unquoted’ or ‘private’ companies), the most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.
    • For companies whose shares are listed on an exchange (such as the AQSE or AIM), the most likely way to get your money back is if the business is bought by another business or your shares are sold on that exchange. The latter can only occur if there is a willing buyer.
    • If you are investing in a start-up or EIS qualifying business, you should not expect to get your money back through dividends. Such businesses rarely pay these.
  4. Don’t put all your eggs in one basket
    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.
    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments. (See https://www.fca.org.uk/investsmart/5-questions-ask-you-invest).
  5. The value of your investment can be reduced
    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.
    • These new shares could have additional rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website at www.fca.org.uk/investsmart

Important notice

Please note that you have clicked to leave the Seneca Partners website. Seneca Partners Limited is Authorised and Regulated by the Financial Conduct Authority (FCA). The website you have requested to visit is an unregulated Seneca business and you will not therefore be afforded the protections offered by an FCA authorised and regulated business.

Please click ok below to continue to the Seneca Social Housing website.

OK

Important notice

Please note that you have clicked to leave the Seneca Partners website. Seneca Partners Limited is Authorised and Regulated by the Financial Conduct Authority (FCA). The website you have requested to visit is an unregulated Seneca business and you will not therefore be afforded the protections offered by an FCA authorised and regulated business.

Please click ok below to continue to the Seneca Property Investments website.

OK